DIA Europe 2019 has ended
Back To Schedule
Thursday, February 7 • 09:15 - 10:15
#S0805: China - Update on the Regulatory Environment

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Session

• Latest Changes in NMPA • Update on the (Clinical) Development Environment /Regulations/Approvals in China • Update on the GCP/GMP Environment in China and its Changes


Joseph C. Scheeren, PharmD


The Latest Progress of the Drug Regulatory Environment in China
Jianqing Chang, DrMed

China Speed: An Overview of Fast Evolving Biopharma Innovation Ecosystem in China
Walter Beck, DVM

Lingshi Tan, PhD


Walter Beck

VP RD CO Head of Business Excellence & Innovation, Bayer AG
More than 30 years work experience in Clinical Development at Schering and Bayer. Different roles in Clinical Development and Clinical Operations including Global Data Management Head. Since 2014 Head of Business Excellence & Innovation in Clinical Operations in Bayer Pharmaceuticals... Read More →
avatar for Joseph Scheeren

Joseph Scheeren

Chair of the Board of Directors, DIA
Joseph Scheeren, Pharm.D. is Dutch and studied pharmacy at the University of Leiden. He has a long global career in the pharmaceutical industry in development and in Regulatory Affairs (RA). He has joined Bayer in 2004 as SVP, Head of RA and Development responsible for the US. He... Read More →
avatar for Lingshi Tan

Lingshi Tan

Chairman and Chief Executive Officer, dMed Biopharmaceutical Co., Ltd., China
Lingshi Tan, PhD, is Chairman and CEO of dMed Global, a Next Generation global clinical development partner, with unique strengths in China and the US, that is committed to helping companies accelerate delivery of solutions to patients worldwide. Prior to founding dMed, Dr. Tan was... Read More →

Thursday February 7, 2019 09:15 - 10:15 CET
K2 Austria Center Vienna Bruno-Kreisky-Platz 1 1220 Vienna Austria